RA Flashcards

1
Q

What is Rheumatoid Arthritis?

A
  • Autoimmune, systemic inflammatory disease that typically affects small joints
  • Chronic, persistent synovial inflammation leads to destruction of articular cartilage and bone (synovial membrane is what surrounds the joint).
  • Causes decline in joint function and progressive disability
  • Between 0.5-1% of adults have condition, relatively common disease (Smolen et al., 2016)
    Reduced life expectancy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the clinical featurs of RA?

A
  • The most common feature is a symmetrical polyarthritis (same type of the joint on both left and right of the body) with pain and swelling affecting the small joints of the hands and feet
  • Patients with RA can experience morning stiffness in and around the affected joints which improves with activity
  • Systemic features: increased incidence of atherosclerosis and vasculitis (inflammation of the blood vessels – affects the cardiovascular system) (same type of inflammation on left and right of the body)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What would lab results show?

A
  • increased level of acute phase reactants (e.g. C reactive protein (CRP)
  • increased level of erythrocyte sedimentation rate (ESR)) (going down much faster – well known marker for increased inflammation)
  • presence of autoantibodies such as RF and ACPA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the Symptoms of RA?

A

• Swelling, tenderness pain, warm when touch joint

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the Risk Factors of RA?

A
  • Gender: Female gender (3:1 – 3 times more likely than men, perhaps hormonal involvement)
  • Genetic predispositions: There are strong associations between HLA-DR4 and HLA-DR1 and RA, which may be familial or non-familial (sporadic).
  • Heritability 53% - 68% - genes play a big role
  • HLA peptide binding grove - “Shared epitope”
  • The protein tyrosine phosphatase 22 gene (PTPN22)

CTLA4 – negative regulator, STAT4,IL-6, NF-Kb, PAD enzymes – involved in regulating the immune function

  • Age - increases with age (60+).
  • Environmental risk factors
  • Smoking
  • Infection
  • Microbes: P.gingivalis – bacteria in the gums – periodontitis. This bacterium carries the enzymes which generate auto antibodies
  • Dust/silica exposure
  • Diet
  • Hormonal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the antibodies in RA?

A

• Rheumatoid factors (RFs) are autoantibodies that recognize the Fc portion of immunoglobulin G molecules

RFs have numerous causes in addition to RA and therefore have limited specificity for RA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the autoantibodies associated with RA?

A

Autoantibodies to citrullinated protein/peptide antigens (ACPAs)

PAD enzymes in the presence of Ca can convert Arginine into Citrulline

The anticyclic citrullinated peptide (anti-CCP) assay broadly detects antibodies against citrullinated proteins (ACPAs) and has high specificity and excellent sensitivity in RA

Anti-CCP/ACPAs precede the onset of clinical RA and are associated with more severe disease, making them useful as diagnostic and prognostic tools

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How many points of the ACR/EULAR criteria does someone need to be diagnosed as having RA?

A

Need 4/7 to be diagnosed

  1. Morningstiffness
  2. Arthritis of 3 or more joints
  3. Arthritis of hand joints
  4. Symmetric arthritis
  5. Rheumatoid arthritis
  6. Serum Rheumatoid factor
  7. Radiographic changes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Describe the pathogenesis of RA

A
  • Macrophages produce loads of pro-inflammatory cytokines
  • Neutrophils become activated
  • No control – cause uncontrollability and then damage of the joint. Leads to new cell epitopes which will be presented to the cells
  • Lymph node: has antigen presenting cells such as dendritic cells which will present newly self-modified proteins to the t cells. Interaction Is between MHC molecule and T cell. T cell activated and immune response activated
  • B cells become activate and proliferate and produce autoantibodies against cytrillinated proteins.
  • Synovial fibroblasts – they become activate and start to proliferate. They invade the joint towards the cartilage. They produce matrix degrading enzyme which causes cartilage breakdown.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the DAS28 score?

A

Shows you the level of disease activity

Clinician will:

  • Count the number of swollen joints (out of the 28)
  • Count the number of tender joints (out of the 28)
  • Take blood to measure the erythrocyte sedimentation rate (ESR) or C reactive protein (CRP)

Ask patient to make a ‘global assessment of health’ (indicated by marking a 10 cm line between very good and very bad)
Results are then fed into a mathematical formula to produce the overall disease activity score
• DAS28 > 5.1 - active disease
• DAS28 < 3.2 - low disease activity
• DAS < 2.6 – remission

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

When is the window of opportunity to treat RA?

A

3 MONTHS (First onset of clinical symptoms)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the first line treatment for RA?

A

Methotrexate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the conventional synthetic DMARDs?

A

methotrexate, sulfasalazine, leflunomide and hydroxychloroquine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the Targeted synthetic DMARDs (tsDMARD?

A

tofacitinib (Janus kinase signalling molecule inhibitor)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe the pharmacological treatment pathway of RA.

A
  1. Monotherapy with csDMARD - MTX, Sulfasalazine, leflunomaide - within 3 months
    Alternative: Hydroxychloroquine
  2. Short term bridging with glucocorticoid
  3. Offer additional csDMARD if disease not improving despite increase in dose.
  4. Inadequate control with csDMARD. Try bDMARD - TNFa inhibitor
  5. Inadquate response -> Rituximab with MTX

Symptom control with NSAID and PPI (Offer lowest dose).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly